Proresolving action of docosahexaenoic acid monoglyceride in lung inflammatory models related to cystic fibrosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 53, Issue 4, 2015, Pages 574-583

  Morin, Caroline ^a,b   Cantin, André M ^c   Rousseau, Éric ^b   Sirois, Marco ^c   Sirois, Chantal ^c   Rizcallah, Edmond ^c   Fortin, Samuel ^a  

^a SCF Pharma   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Docosahexaenoic acid; Inflammation; Lung

Indexed keywords

ANTIINFLAMMATORY AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOCOSAHEXAENOIC ACID MONOACYLGLYCERIDE; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; MUCIN 5AC; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; CFTR PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOACYLGLYCEROL; MUC5AC PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL FREE SYSTEM; CELL LYSATE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID ANALYSIS; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPID ANALYSIS; LIPID COMPOSITION; LUNG FIBROSIS; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFLAMMATION; WESTERN BLOTTING; BRONCHUS; CELL LINE; DRUG SCREENING; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; BRONCHI; CELL LINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG EVALUATION, PRECLINICAL; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; LUNG; MONOGLYCERIDES; MUCIN 5AC; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84942849837     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0223OC     Document Type: Article

References (38)

1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245: 1073-1080.
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
3. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, Robberecht E, Döring G. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002;1:51-75.
4. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF Quality Assurance (CFQA) project. Thorax 2002;57:596-601.
5. Christophe A, Robberecht E. Current knowledge on fatty acids in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 1996;55: 129-138.
6. Beharry S, Ackerley C, Corey M, Kent G, Heng YM, Christensen H, Luk C, Yantiss RK, Nasser IA, Zaman M, et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;292: G839-G848.
7. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in CFTR(2/2) mice. Proc Natl Acad Sci USA 1999; 96:13995-14000.
8. Coste TC, Armand M, Lebacq J, Lebecque P, Wallemacq P, Leal T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem 2007;40:511-520.
9. De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. JPEN J Parenter Enteral Nutr 2003;27:52-57.
10. Katz DP, Manner T, Furst P, Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 1996;12:334-339.
11. Leggieri E, De Biase RV, Savi D, Zullo S, Halili I, Quattrucci S. Clinical effects of diet supplementation with DHA in pediatric patients suffering from cystic fibrosis. Minerva Pediatr 2013;65:389-398.
12. Olveira G, Olveira C, Acosta E, Espíldora F, Garrido-Sánchez L, García- Escobar E, Rojo-Martínez G, Gonzalo M, Soriguer F. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol 2010; 46:70-77.
13. Panchaud A, Sauty A, Kernen Y, Decosterd LA, Buclin T, Boulat O, Hug C, Pilet M, Roulet M. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr 2006;25:418-427.
14. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011;111:5922-5943.
15. Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radic Biol Med 2012;53:160-171.
16. Fortin S. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. Patent nos. US819690, 2012, US8222295, 2012.
17. Fortin S. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. Patent nos. CA2672513, 2008, CA2677670, 2010, US8119690, 2011.
18. Morin C, Fortin S, Cantin AM, Rousseau E. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. Am J Respir Cell Mol Biol 2011;45:366-375.
19. Morin C, Fortin S, Cantin AM, Sirois M, Sirois C, Rizcallah E, Rousseau É. Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma. Recent Patents Anticancer Drug Discov 2013;8:319-334.
20. Shen BQ, Finkbeiner WE, Wine JJ, Mrsny RJ, Widdicombe JH. Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl2 secretion. Am J Physiol 1994;266:L493-L501.
21. Palmer ML, Fahrenkrug SC, O'Grady SM. RNA interference and ion channel physiology. Cell Biochem Biophys 2006;46:175-191.
22. Mitchell G, Grondin G, Bilodeau G, Cantin AM, Malouin F. Infection of polarized airway epithelial cells by normal and small-colony variant strains of Staphylococcus aureus is increased in cells with abnormal cystic fibrosis transmembrane conductance regulator function and is influenced by NF-kB. Infect Immun 2011;79: 3541-3551.
23. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986;27:114-120.
24. Cantin AM, Bilodeau G, Larivée P, Richter MV. Plasma biomarkers and cystic fibrosis lung disease. Clin Invest Med 2012;35:E173-E181.
25. Morin C, Sirois M, Echave V, Rousseau E. CPI-17 silencing-reduced responsiveness in control and TNF-a-treated human bronchi. Am J Respir Cell Mol Biol 2008;39:638-643.
26. Morin C, Fortin S, Cantin AM, Rousseau É. MAG-EPA resolves lung inflammation in an allergic model of asthma. Clin Exp Allergy 2013; 43:1071-1082.
27. Blackwell TS, Stecenko AA, Christman JW. Dysregulated NFkappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. Am J Physiol Lung Cell Mol Physiol 2001; 281:L69-L70.
28. Joseph T, Look D, Ferkol T. NF-kappaB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2005;288:L471-L479.
29. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-569.
30. Cruz-Hernandez C, Thakkar SK, Moulin J, Oliveira M, Masserey- Elmelegy I, Dionisi F, Destaillats F. Benefits of structured and free monoacylglycerols to deliver eicosapentaenoic (EPA) in a model of lipid malabsorption. Nutrients 2012;4:1781-1793.
31. Freedman SD, Weinstein D, Blanco PG, Martinez-Clark P, Urman S, Zaman M, Morrow JD, Alvarez JG. Characterization of LPSinduced lung inflammation in CFTR2/2 mice and the effect of docosahexaenoic acid. J Appl Physiol (1985) 2002;92: 2169-2176.
32. Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot J, Peault B, Puchelle E. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000;23: 121-127.
33. Kirkham S, Sheehan JK, Knight D, Richardson PS, Thornton DJ. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002;361:537-546.
34. Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med 2007; 175:816-821.
35. Kreda SM, Davis CW, Rose MC. CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med 2012; 2:a009589.
36. Li JD, Dohrman AF, Gallup M, Miyata S, Gum JR, Kim YS, Nadel JA, Prince A, Basbaum CB. Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc Natl Acad Sci USA 1997;94: 967-972.
37. Morin C, Fortin S, Rousseau E. 19,20-EpDPE, a bioactive CYP450 metabolite of DHA monoacyglyceride, decreases Ca2? sensitivity in human pulmonary arteries. Am J Physiol Heart Circ Physiol 2011; 301:H1311-H1318.
38. Morin C, Sirois M, EchavéV, Albadine R, Rousseau E. 17,18-epoxyeicosatetraenoic acid targets PPARg and p38 mitogenactivated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. Am J Respir Cell Mol Biol 2010;43:564-575.